Mesenchymal Stem Cells as Vehicles for Gene Delivery

Mosca, Joseph D.; Hendricks, Jacobus; Buyaner, Diana; Davis-Sproul, Janice; Chuang, L C; Majumdar, Manas K.; Chopra, Rajesh; Barry, Frank; Murphy, Mary; Thiede, Mark A.; Junker, Uwe; Rigg, Richard; Forestell, Sean; Böhnlein, Ernst; Storb, Rainer; Sandmaier, Brenda M.

doi:10.1097/00003086-200010001-00011

Cited by 113 publications

(79 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MSCs appear reasonably receptive to transduction with recombinant adenoviral vectors, [90][91][92] retrovirus, 33,93 lentivirus and AAV (unpublished observation). Currently, several laboratories are studying means to apply this technology to MSCs in vivo.…”

Section: Gene Transfer To Chondroprogenitor Cellsmentioning

confidence: 85%

Gene-based approaches for the repair of articular cartilage

2004

View full text Add to dashboard Cite

Section: Gene Transfer To Chondroprogenitor Cellsmentioning

confidence: 85%

Gene-based approaches for the repair of articular cartilage

2004

View full text Add to dashboard Cite

“…When using retroviruses, the transduction is confined to replicating cells, and therefore a 100% transduction efficiency, was not expected [29]. In a large study, Mosca et al investigated optimal parameters required to transduce BMSC's from eight different species, including the goat [30]. For goat BMSC's they reported a relatively low transduction efficiency with the amphotropic receptor binding envelope (< 10%) compared to 5OYn when using their xenotropic (ProPak-X) packaging cell line.…”

Section: Discussionmentioning

confidence: 99%

“…bone [24,32], cartilage [11,35], and tendon [15]. Furthermore, these cells have been investigated as a delivery vehicle for gene therapy [1, 26,30]. The application of BMSC's in tissue engineering of bone has progressed fast and some investigators have already made steps towards clinical application [34,36].…”

mentioning

confidence: 99%

Genetic marking with the ΔLNGFR‐gene for tracing goat cells in bone tissue engineering

Kruyt

Stijns

Fedorovich

et al. 2004

Journal Orthopaedic Research

View full text Add to dashboard Cite

The use of bone marrow derived stromal cells (BMSC's) for bone tissue engineering has gained much attention as an alternative for autologous bone grafting. Little is known however, about the survival and differentiation of the cells, especially in the clinical application. The aim of this study was to develop a method to trace goat BMSC's in vivo. We investigated retroviral genetic marking, which allows stable expression of the label with cell division.Goat BMSC's were subjected to an amphotropic envelope containing a MoMuLV-based vector expressing the human low affinity nerve growth factor receptor (ALNGFR). Labeling efficiency and effect on the cells were analyzed. Furthermore, transduced cells were seeded onto porous ceramic scaffolds, implanted subcutaneously in nude mice and examined after successive implantation pe riod s .Flow cytometry indicated a transduction efficiency of 40-60'%,. Immunohistochemistry showed survival and subsequent bone formation of the gene-marked cells in vivo. Besides, marked cells were also found in cartilage and fibrous tissue. These findings indicate the maintenance of the precursor phenotype following gene transfer as well as the ability of the gene to be expressed following differentiation. We conclude that retroviral gene marking with ALNGFR is applicable to trace goat BMSC's in bone tissue engineering research.

show abstract

“…MSCs strongly protected renal function as reflected by significantly lower blood urea nitrogen values (Morigi et al, 2004). In a canine model, MSCs were also shown to migrate to the bone marrow after myeloablation of dogs via total body irradiation (Mosca et al, 2000). After MSC transfusion, 58% of the bone marrow samples analyzed were transgene positive.…”

Section: Migration Of Mscs Towards Injured Tissuementioning

confidence: 99%

“…In case of tissue damage, MSCs can be mobilized by signals such as cytokines and chemokines released from the damaged tissue and migrate to the sites of injury to participate in wound repair and tissue regeneration (Ramirez et al, 2006). Animal studies demonstrated that MSCs migrate to injured sites in the body, including the heart (Assis et al, 2010;Detante et al, 2009;Kraitchman et al, 2005;Wu et al, 2003), kidney (Herrera et al, 2007;Morigi et al, 2004), skin (Li et al, 2006), and bone (Horwitz et al, 1999;Mackenzie & Flake, 2001;Mosca et al, 2000). In rats bearing Lewis cardiac allografts, Wu et al (Wu et al, 2003) found that IV injected -galactosidase (lacZ) labeled MSCs can migrate into lesions of chronic rejection in the cardiac grafts and home to the bone marrow.…”

Section: Migration Of Mscs Towards Injured Tissuementioning

confidence: 99%